- Home
- MTNB vs NERV Comparison
MTNB vs NERV Comparison
Compare MTNB & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- NERV
- Stock Information
- Founded
- MTNB 2013
- NERV 2007
- Country
- MTNB United States
- NERV United States
- Employees
- MTNB N/A
- NERV N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- MTNB Health Care
- NERV Health Care
- Exchange
- MTNB Nasdaq
- NERV Nasdaq
- Market Cap
- MTNB 16.1M
- NERV 18.3M
- IPO Year
- MTNB N/A
- NERV 2014
- Fundamental
- Price
- MTNB $0.60
- NERV $2.26
- Analyst Decision
- MTNB Hold
- NERV Hold
- Analyst Count
- MTNB 1
- NERV 1
- Target Price
- MTNB N/A
- NERV $5.00
- AVG Volume (30 Days)
- MTNB 578.7K
- NERV 24.1K
- Earning Date
- MTNB 11-13-2024
- NERV 11-05-2024
- Dividend Yield
- MTNB N/A
- NERV N/A
- EPS Growth
- MTNB N/A
- NERV N/A
- EPS
- MTNB N/A
- NERV N/A
- Revenue
- MTNB N/A
- NERV N/A
- Revenue This Year
- MTNB N/A
- NERV N/A
- Revenue Next Year
- MTNB N/A
- NERV N/A
- P/E Ratio
- MTNB N/A
- NERV N/A
- Revenue Growth
- MTNB N/A
- NERV N/A
- 52 Week Low
- MTNB $0.50
- NERV $2.07
- 52 Week High
- MTNB $21.50
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- MTNB 26.12
- NERV 39.37
- Support Level
- MTNB $0.53
- NERV $2.08
- Resistance Level
- MTNB $0.67
- NERV $2.29
- Average True Range (ATR)
- MTNB 0.13
- NERV 0.10
- MACD
- MTNB 0.09
- NERV 0.00
- Stochastic Oscillator
- MTNB 22.41
- NERV 33.33
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.